Your browser is no longer supported. Please, upgrade your browser.
BCDA BioCardia, Inc. daily Stock Chart
BioCardia, Inc.
Index- P/E- EPS (ttm)-3.00 Insider Own3.90% Shs Outstand7.15M Perf Week32.13%
Market Cap36.75M Forward P/E- EPS next Y-0.96 Insider Trans1.46% Shs Float2.23M Perf Month37.07%
Income-14.80M PEG- EPS next Q-0.47 Inst Own3.70% Short Float0.82% Perf Quarter20.94%
Sales0.60M P/S61.25 EPS this Y-13.00% Inst Trans- Short Ratio0.66 Perf Half Y-48.60%
Book/sh0.86 P/B5.98 EPS next Y45.40% ROA-237.90% Target Price18.33 Perf Year-75.70%
Cash/sh1.24 P/C4.13 EPS next 5Y- ROE-784.80% 52W Range3.15 - 17.50 Perf YTD39.67%
Dividend- P/FCF- EPS past 5Y- ROI-371.10% 52W High-70.63% Beta2.15
Dividend %- Quick Ratio2.30 Sales past 5Y18.50% Gross Margin27.00% 52W Low63.17% ATR0.62
Employees27 Current Ratio2.30 Sales Q/Q100.00% Oper. Margin- RSI (14)60.53 Volatility23.99% 14.15%
OptionableNo Debt/Eq0.00 EPS Q/Q24.50% Profit Margin- Rel Volume0.15 Prev Close5.06
ShortableYes LT Debt/Eq0.00 EarningsNov 14 Payout- Avg Volume27.49K Price5.14
Recom2.00 SMA2025.05% SMA5026.62% SMA200-26.88% Volume4,116 Change1.58%
Jan-14-20 08:00AM  Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter GlobeNewswire -6.69%
Jan-08-20 08:00AM  BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery GlobeNewswire +13.91%
Dec-30-19 10:40AM  Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely? Simply Wall St. -5.90%
Nov-19-19 05:24PM  BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights GlobeNewswire
Nov-11-19 07:44AM  Investors Who Bought BioCardia (NASDAQ:BCDA) Shares A Year Ago Are Now Down 80% Simply Wall St. -5.83%
Oct-28-19 08:00AM  BioCardia to Present at Dawson James Securities 5th Annual Small Cap Growth Conference GlobeNewswire
Oct-08-19 08:00AM  BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 GlobeNewswire
Oct-02-19 08:00AM  BioCardia Announces the Appointment of Two New Board Members GlobeNewswire -9.91%
Oct-01-19 08:00AM  BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures GlobeNewswire +15.21%
Sep-16-19 08:00AM  BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned GlobeNewswire
Aug-21-19 08:00AM  BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights GlobeNewswire
Aug-08-19 08:30AM  BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery GlobeNewswire
Aug-06-19 04:05PM  BioCardia Announces Closing of $10.0 Million Public Offering GlobeNewswire
Aug-02-19 09:45AM  BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq GlobeNewswire -64.29%
Jul-25-19 06:00AM  BioCardia Signs Exclusive Development Agreement With AstraZeneca GlobeNewswire +14.79%
Jun-12-19 08:00AM  BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery GlobeNewswire +35.11%
Jun-06-19 08:00AM  BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange GlobeNewswire
May-23-19 03:23PM  Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardias Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class GlobeNewswire -16.00%
May-20-19 08:00AM  BioCardia Reports 2019 First Quarter Financial Results and Business Highlights GlobeNewswire +6.53%
May-08-19 08:00AM  BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart GlobeNewswire
Apr-02-19 08:00AM  BioCardia Reports 2018 Financial Results and Recent Business Highlights Business Wire
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Altman PeterPresident and CEODec 31Buy3.674,00014,676163,411Jan 03 03:51 PM